Perrigo Company Plc on Monday posted quarterly earnings below estimates and said it would sell its underperforming generic drugs business for $1.55 billion, as the consumer healthcare products company sharpens focus on its core business.
The sale, to private equity firm Altaris Capital Partners, is expected to close by the end of the third quarter, Perrigo said.
“After the transaction closes, Perrigo expects to have more than $2 billion in cash available to advance its consumer self-care strategy, preferably through prudent and revenue accretive M&A,” Chief Executive Officer Murray Kessler said.
Lower sales of Perrigo’s cold and cough products drove it to a net loss of $162.6 million in the fourth quarter versus a $146.1 million profit last year.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.